8-K: Longeveron CEO Employment Agreement Revised

Longeveron Inc. has revised its employment agreement with CEO Stephen Willard, adjusting salary deferral, bonus structure, severance, and equity vesting terms.

Summary

• Longeveron Inc. has entered into a revised employment agreement with its CEO, Stephen Willard, effective July 8, 2026.
• The agreement removes the deferral period for Mr. Willard's $500,000 annual base salary.
• Mr. Willard is eligible for an annual cash bonus with a target of 45% of his base salary, with 80% tied to corporate goals and 20% discretionary.
• Severance provisions have been updated, including enhanced benefits in case of termination without cause or for good reason, particularly following a Change in Control.
• Equity incentive awards, including restricted stock units and stock options, will now vest quarterly over a three-year period, a change from the previous four-year schedule.
• The agreement also details terms for disability, termination for cause, and cooperation post-employment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily concerns the adjustment of an executive employment agreement rather than significant operational or financial performance updates.

Positives

• CEO's base salary of $500,000 is no longer subject to deferral.
• CEO is eligible for an annual cash bonus with a target of 45% of base salary.
• Enhanced severance package for termination without cause or for good reason, especially post-Change in Control.
• Accelerated vesting schedule for equity awards (RSUs and stock options) from four years to three years.
• CEO can work remotely from a location of choice, with required travel to Miami as needed.

Negatives

• Severance payments are contingent on the execution and non-revocation of a release of claims.
• The discretionary portion of the annual bonus (20%) is subject to the Compensation Committee's sole discretion.
• Termination for Cause, death, or voluntary resignation (not for Good Reason) results in no severance beyond accrued amounts.
• The agreement includes provisions for potential reduction of severance benefits to avoid excise taxes under Section 280G of the Code.

Risks

• The agreement contains forward-looking statements subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially.
• Potential for 'Cause' for termination includes material breach of agreements, felony conviction, gross negligence, fraud, or material violation of company policy.
• Potential for 'Good Reason' for resignation includes material reduction in title, authority, duties, responsibilities, or compensation.
• The company's ability to meet corporate goals, which impacts the bonus payout, is subject to market and operational risks.

Future Outlook

The agreement outlines terms for continued employment and potential future compensation and benefits, including severance and equity vesting, contingent on various performance and termination conditions. The company's ability to achieve corporate goals will impact bonus payouts.

Management Comments

• The Revised Agreement amends and restates the prior letter agreement with Mr. Willard dated February 11, 2026 and will govern Mr. Willard's continued employment with the Company.
• Mr. Willard's entitlement to receive a base salary of $500,000 per year is no longer subject to the previously disclosed deferral period.
• The bonus will have an initial target amount of forty-five percent (45%) of Mr. Willard's base salary of which eighty percent (80%) of that target bonus will be based upon the achievement of the agreed upon corporate goals of the Company and twenty percent (20%) will be at the discretion of the Board of Directors of the Company and/or the Compensation Committee of the Board.

Industry Context

StockSavvy.ai notes that revisions to executive employment agreements, particularly concerning base salary, bonus structures, severance, and equity vesting, are common in the biotechnology and pharmaceutical sectors as companies navigate clinical development, regulatory approvals, and market dynamics. These adjustments aim to retain key leadership while aligning incentives with company performance and shareholder value.

Comparison to Industry Standards

• The CEO's base salary of $500,000 is within the typical range for CEOs of small to mid-cap biotechnology companies, depending on the company's stage of development and market capitalization.
• A target bonus of 45% of base salary is also standard, with the split between performance-based and discretionary components being a common practice.
• Severance packages, especially those triggered by a Change in Control, often include 12-24 months of base salary and continued benefits, which aligns with the provisions for Mr. Willard.
• Accelerated vesting of equity awards over three years is a common incentive to retain executives, though some companies may offer shorter or longer vesting periods based on strategic goals.

Management Changes

Stakeholder Impact

• Shareholders: The revised agreement clarifies CEO compensation and incentives, potentially impacting long-term alignment and retention, but does not immediately alter share value.
• Employees: The bonus structure and equity vesting for the CEO may set precedents or reflect company-wide compensation philosophies.
• Management: The agreement provides clarity on the CEO's remuneration and severance, potentially influencing morale and retention within the executive team.

Next Steps

• Mr. Willard will continue his employment as CEO of Longeveron Inc.
• Annual bonuses will be determined based on corporate goals and board discretion.
• Equity awards will vest quarterly over a three-year period.
• Severance benefits will be paid according to the terms outlined in the agreement upon qualifying termination events.

Key Dates

Keywords

CEO employment agreement, Longeveron, Stephen Willard, compensation, severance package, equity awards, Form 8-K, employment terms